Grant Life Sciences' malaria, dengue fever tests ready for distribution

By E. Janene Geiss

Philadelphia, Oct. 24 - Grant Life Sciences announced Monday that it expects to begin generating revenue on sales of its rapid tests for malaria and dengue fever.

According to a company news release, officials said the tests may begin making money within the next 30 days because products are now being manufactured and prepared for shipment. Distribution channels are in place, officials said.

The tests were acquired along with rapid tests for HIV-1 and HIV-2 earlier this year from AccuDx, a biotechnology company based in LaJolla, Calif.

The agreement gives Grant Life Sciences control of the exclusive rights to AccuDx's rapid tests as well as its proprietary colloidal gold reagent. The agreement establishes manufacturing of these products in AccuDx's facility in Tijuana, Mexico, officials said.

"We are very pleased to report that Grant Life Sciences has been successful in re-establishing the first of several distribution channels previously utilized by AccuDx," Dr. Hun-Chi Lin, president and chief scientist at Grant Life Sciences, said in the release.

Murray, Utah-based Grant Life Sciences develops products to improve the efficiency of detecting and diagnosing cervical cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.